Physician profile
John H Stasiewicz
NPI 1033100482
$7,916.56
in general payments reported to CMS, 2019-2025
43 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $293 · 2022: $510 · 2023: $1,885 · 2024: $1,879 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,731.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,103.76 | 2019-2025 | Airsupra, Farxiga, Evusheld |
| Lilly USA, LLC | $963.86 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.60 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Novo Nordisk INC | $791.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $652.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $560.70 | 2023-2025 | Qulipta, Ubrelvy, Botox |
| Merck Sharp & Dohme LLC | $410.74 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amgen INC. | $336.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $270.85 | 2019-2025 | |
| Exact Sciences Corporation | $197.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sk Life Science, INC. | $187.20 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $184.67 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $139.48 | 2022-2025 | |
| Sanofi Pasteur INC. | $139.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $128.90 | 2019-2023 | Xarelto |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stasiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.